What “Payout Status” Means for an IRA When a Senior Applies for Medicaid Long-Term Care

“Payout status” is a Medicaid-specific term describing how retirement accounts are treated when a senior applies for long-term care coverage. Medicaid distinguishes between retirement accounts that are being actively distributed and those that are not. This distinction determines whether the IRA is counted as an asset that must be spent down or whether it is exempt and allowed to remain intact.

1. Core Definition of Payout Status

An IRA is considered in payout status when the owner is receiving regular, periodic distributions from the account. These distributions must be scheduled, ongoing, and actuarially reasonable. Medicaid evaluates whether the IRA is being treated as a true retirement income source rather than a liquid asset available for spend-down.

If the IRA is in payout status, Medicaid counts only the monthly distribution as income. The principal inside the IRA is exempt and does not need to be spent down. This allows seniors to preserve the IRA while qualifying for long-term care coverage.

2. How Seniors Enter Payout Status

Seniors automatically enter payout status when they begin taking Required Minimum Distributions (RMDs). Federal law requires RMDs beginning at age 73. Once RMDs begin, the IRA is considered in payout status for Medicaid purposes. Seniors may also voluntarily elect periodic distributions that meet Medicaid’s criteria even before RMD age.

Medicaid requires that distributions be periodic and actuarially sound. This means the payout schedule must be consistent with life expectancy tables and cannot be structured to delay distributions indefinitely. Monthly, quarterly, or annual distributions all qualify as long as they follow a reasonable schedule.

3. Why Payout Status Matters for Medicaid Eligibility

Medicaid distinguishes between countable and exempt assets. Retirement accounts in payout status are treated as exempt assets. Only the income generated from the distributions is counted toward Medicaid’s income rules. This allows seniors to preserve the principal in their retirement accounts while still qualifying for long-term care coverage.

If an IRA is not in payout status, Medicaid treats the entire account as a countable resource. This means the IRA may need to be liquidated and spent down to meet Medicaid’s asset limits. Entering payout status prevents liquidation and protects the IRA.

4. Treatment of IRAs for Married Couples

When one spouse enters long-term care and the other remains in the community, the community spouse’s IRA is fully exempt regardless of payout status. Medicaid does not count the community spouse’s retirement accounts toward eligibility. The institutionalized spouse’s IRA must be in payout status to be exempt.

If both spouses enter long-term care, each IRA must be evaluated individually. IRAs in payout status remain exempt. IRAs not in payout status may be counted and may require conversion to payout status to avoid spend-down.

5. Practical Example for a Senior

A senior age 75 with a $50,000 IRA is already required to take RMDs. Because the IRA is in payout status, Medicaid counts only the monthly RMD amount as income. The $50,000 principal remains protected and does not need to be spent down. This allows the senior to qualify for long-term care coverage while preserving the IRA.

If the senior were younger than 73 and not taking distributions, Medicaid would treat the entire $50,000 as a countable asset. The senior could elect periodic distributions to place the IRA in payout status and protect the principal.

6. Overall Meaning of Payout Status

Payout status is a protective classification that allows seniors to preserve retirement accounts during Medicaid long-term care eligibility. By ensuring that the IRA is in payout status, seniors can avoid liquidation and maintain the principal while receiving long-term care coverage. This status is essential for asset preservation and financial stability during long-term care.

Nevada Medicaid Treatment of Home and IRA for Couples Age 65+ Entering Skilled Nursing, Custodial Care, or Cancer Treatment

This document explains how Nevada Medicaid evaluates a $500,000 home and a $50,000 IRA when one or both spouses age 65 or older enter skilled nursing, custodial care, or require cancer treatment. Nevada follows federal Medicaid long-term care rules, including spousal impoverishment protections, home exemptions, and estate recovery limitations.

1. Treatment of the $500,000 Home

Nevada Medicaid treats the primary residence as an exempt asset as long as one spouse continues living in the home. The value of the home does not matter; Nevada does not impose a home equity cap when a community spouse resides there. If one spouse enters long-term care and the other remains at home, the home is fully protected and cannot be counted toward Medicaid eligibility.

If both spouses enter long-term care simultaneously, the home remains exempt if either spouse expresses an intent to return home. Nevada accepts this intent even if return is medically unlikely. The home therefore remains protected during both spouses’ lifetimes.

Estate recovery in Nevada occurs only after both spouses have died. Recovery applies only to assets passing through probate. If the home is placed in a living trust or otherwise avoids probate, Nevada cannot recover against it. This allows the home to remain protected even after both spouses’ deaths.

2. Treatment of the $50,000 IRA

Nevada follows federal Medicaid rules for retirement accounts. If the IRA belongs to the community spouse, it is fully exempt and does not count toward Medicaid eligibility. The community spouse may retain the IRA without spend-down requirements.

If the IRA belongs to the spouse entering long-term care, Nevada counts the IRA as a resource unless it is in payout status. When the IRA is in periodic required minimum distribution status, Nevada treats the principal as exempt and counts only the monthly distribution as income. This allows the IRA to be preserved rather than liquidated.

If both spouses enter long-term care, each IRA must be evaluated individually. IRAs in payout status remain protected. IRAs not in payout status may be counted and may require conversion to payout status to avoid spend-down.

3. Spousal Impoverishment Protections

Nevada applies federal spousal impoverishment rules when one spouse enters long-term care. The community spouse is allowed to retain a significant portion of the couple’s assets under the Community Spouse Resource Allowance. In 2026, the community spouse may keep approximately $154,000 in countable assets, in addition to exempt assets such as the home and retirement accounts.

The community spouse also retains all personal income. None of the community spouse’s income is taken to pay for the institutionalized spouse’s care. The institutionalized spouse contributes income toward the cost of care, minus a small personal needs allowance.

4. If Both Spouses Enter Skilled Nursing or Custodial Care

When both spouses enter long-term care, Nevada Medicaid evaluates them as a couple. The home remains exempt if either spouse intends to return home. The IRA remains exempt if in payout status. Countable assets must be reduced to the couple’s Medicaid resource limit, which is significantly lower than the spousal impoverishment allowance. Exempt assets, including the home and properly structured IRAs, remain protected.

After both spouses pass away, Nevada may pursue estate recovery. Recovery applies only to probate assets. If the home is held in a living trust or passes outside probate, Nevada cannot recover against it.

5. Cancer Treatment Under Nevada Medicaid

Cancer treatment falls under standard Medicaid medical coverage rather than long-term care rules. Asset limits for medical Medicaid differ from long-term care Medicaid. However, for individuals age 65 and older, Nevada uses the federal SSI-related Medicaid rules, which include asset limits but exempt the home and certain retirement accounts. The $500,000 home remains protected. The $50,000 IRA is exempt if in payout status.

If cancer treatment leads to long-term custodial care, the long-term care rules described above apply.

6. Summary Table

Asset	Outcome When One Spouse Enters Care	Outcome When Both Spouses Enter Care
Home ($500,000)	Fully exempt; protected; no spend-down; no lien; no recovery while community spouse lives.	Exempt if either spouse intends to return; protected until both spouses die; avoid probate to prevent recovery.
IRA ($50,000)	Exempt if owned by community spouse; exempt if in payout status for institutionalized spouse.	Exempt if in payout status; may require conversion to payout status to avoid spend-down.
Estate Recovery	No recovery until both spouses have died; home protected while community spouse lives.	Recovery only against probate assets; home protected if placed in trust or otherwise avoids probate.

7. Overall Consequence

In Nevada, a $500,000 home and a $50,000 IRA can both be preserved even if one or both spouses age 65 or older enter skilled nursing, custodial care, or require cancer treatment. The home remains exempt during both spouses’ lifetimes. The IRA remains exempt if properly structured in payout status. Estate recovery can be avoided by ensuring the home does not pass through probate.

Medi-Cal Asset Rules for Cancer Patients Seeking Extra Help

This document explains which assets you may keep and still qualify for Medi-Cal “extra help” programs after a cancer diagnosis. It reflects California’s 2026 Non‑MAGI Medi‑Cal asset rules, including exemptions, countable resources, and special protections for married couples.

Asset Limits for 2026

California reinstated Medi-Cal asset limits on January 1, 2026. The limits are:

Individual: $130,000
Couple: $195,000
Each additional household member: $65,000

These limits apply to Non‑MAGI Medi‑Cal categories, including cancer treatment coverage, long‑term care, and dual‑eligible Medicare + Medi‑Cal programs.

Exempt Assets You May Keep

The following assets do not count toward the Medi-Cal limit and remain fully protected:

Primary Home

Your main residence is exempt as long as you live in it. Its value does not affect eligibility.

One Vehicle

Your primary automobile is exempt regardless of value.

Household Goods and Personal Items

Furniture, clothing, appliances, and personal effects—including jewelry—are excluded.

Retirement Accounts

IRAs and employer-sponsored pensions are exempt if you receive regular periodic payments. For married couples, the community spouse’s retirement accounts are always exempt.

Burial Assets

Exempt burial resources include burial plots, irrevocable prepaid burial plans, and up to $1,500 in designated burial funds.

Business or Self-Support Property

Real property or equipment used for business or self-support does not count toward the limit.

Countable Assets

The following assets do count toward the $130,000 limit:

Cash, checking and savings accounts, stocks, bonds, mutual funds, second vehicles, second homes, and non-exempt financial resources.

Special Rules for Married Couples

If one spouse requires long-term care due to cancer, Medi-Cal applies spousal impoverishment protections:

The institutionalized spouse may keep $130,000.
The community spouse may keep the Community Spouse Resource Allowance (CSRA), which is $162,660 in 2026.

This allows a married household to retain over $290,000 in combined assets while still qualifying.

Upcoming 2027 Change

On July 1, 2027, California’s Medi-Cal asset limit is scheduled to drop sharply:

Individual: $21,000
Couple: $31,000

This change will significantly affect eligibility planning for cancer patients and dual-eligibles.

Comparison Table

Asset Category	Counted?	Notes
Primary Home	No	Fully exempt while occupied
One Vehicle	No	Any value
Retirement Accounts	No (if periodic payments)	Spouse’s IRA always exempt
Burial Assets	No	Plots, prepaid plans, $1,500 fund
Cash / Bank Accounts	Yes	Fully countable
Investments	Yes	Stocks, bonds, mutual funds
Second Home / Vehicle	Yes	Countable
Business Property	No	If used for self-support

International Comparison of Cancer Treatment Costs

Overview

Cancer treatment costs vary dramatically across countries due to differences in healthcare financing, drug pricing regulation, insurance structures, and national reimbursement policies. This document presents a comparative analysis of cancer treatment costs in the United States, the European Union, the United Kingdom, Canada, and Japan, based on 2025–2026 global oncology data.

United States

The United States has the highest cancer treatment costs in the world. New oncology drugs frequently exceed one hundred thousand dollars per year. Multimodal treatment involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy often ranges from fifty thousand to two hundred thousand dollars. Out-of-pocket costs remain substantial even for insured patients, averaging five thousand dollars annually.

High costs are driven by market-based drug pricing, fragmented insurance systems, and limited government negotiation power.

European Union

The European Union benefits from centralized or semi-centralized drug price negotiations, resulting in significantly lower oncology drug prices. Cancer treatment costs typically range from twenty thousand to sixty thousand dollars. Out-of-pocket expenses are minimal due to universal coverage systems.

Survival outcomes for many cancers are comparable to those in the United States, despite substantially lower costs.

United Kingdom

The United Kingdom’s National Health Service (NHS) provides comprehensive cancer treatment at no direct cost to patients. Drug prices are regulated through the National Institute for Health and Care Excellence (NICE), which evaluates cost-effectiveness before approving therapies.

Total treatment costs to the system typically range from fifteen thousand to fifty thousand dollars. Out-of-pocket costs are negligible.

Canada

Canada’s single-payer system provides universal coverage for hospital-based cancer treatments. Drug costs are lower than in the United States but higher than in the United Kingdom. Total treatment costs generally fall between twenty thousand and seventy thousand dollars.

Out-of-pocket costs vary by province, particularly for outpatient oral cancer drugs, but remain significantly lower than in the United States.

Japan

Japan’s universal health insurance system provides broad coverage for cancer treatment. Drug prices are regulated and frequently adjusted downward. Total treatment costs typically range from twenty thousand to fifty thousand dollars. Patients pay a small co-payment, usually capped by income-based limits.

Japan achieves excellent survival outcomes for many cancers, particularly gastric and colorectal cancers, at relatively low cost.

Comparative Summary Table

Region	Typical Cost Range	Patient Out-of-Pocket Cost	Key Features
United States	Fifty thousand to two hundred thousand dollars	High; averages five thousand dollars annually	Market-based pricing; fragmented insurance; highest global drug costs
European Union	Twenty thousand to sixty thousand dollars	Minimal	Centralized price negotiation; universal coverage
United Kingdom	Fifteen thousand to fifty thousand dollars	Negligible	NICE cost-effectiveness review; NHS universal coverage
Canada	Twenty thousand to seventy thousand dollars	Low to moderate depending on province	Single-payer system; regulated drug prices
Japan	Twenty thousand to fifty thousand dollars	Low; capped by income	Universal insurance; frequent price adjustments

Comparative Analysis of Cancer Treatment Duration, Cost, and Survival by Cancer Type

Overview

Cancer treatment varies substantially across cancer types due to differences in tumor biology, staging at diagnosis, and therapeutic modalities. This document presents a comparative analysis of five major cancers: breast cancer, colorectal cancer, lung cancer, prostate cancer, and hematologic malignancies. Each section examines typical treatment duration, cost, and survival outcomes based on 2025–2026 clinical data.

Breast Cancer

Breast cancer treatment often involves multimodal therapy including surgery, radiation, chemotherapy, endocrine therapy, and targeted therapy. Chemotherapy typically lasts three to five months, radiation therapy four to six weeks, and endocrine therapy five to ten years. Targeted therapies such as trastuzumab and pertuzumab may extend for one year or longer.

Total treatment costs range from sixty thousand to one hundred fifty thousand dollars, depending on stage and targeted therapy use. Early‑stage breast cancer has a five‑year survival rate exceeding ninety percent, while metastatic breast cancer has median survival of approximately three years with modern HER2‑targeted and CDK4/6‑targeted therapies.

Colorectal Cancer

Colorectal cancer treatment typically includes surgery followed by adjuvant chemotherapy for stage III disease. Chemotherapy regimens such as FOLFOX or CAPOX last three to six months. Radiation therapy is used primarily for rectal cancer and lasts five to six weeks. Metastatic colorectal cancer treatment may continue indefinitely with chemotherapy and targeted agents.

Total treatment costs range from seventy thousand to two hundred thousand dollars. Stage III colorectal cancer has a five‑year survival rate of approximately sixty‑five percent. Metastatic colorectal cancer has response rates of thirty to forty percent and median survival of twenty to twenty‑four months.

Lung Cancer

Lung cancer treatment varies significantly between non‑small‑cell lung cancer (NSCLC) and small‑cell lung cancer (SCLC). NSCLC treatment may include surgery, chemotherapy, radiation, immunotherapy, and targeted therapy. Chemotherapy typically lasts three to four months, radiation therapy six to seven weeks, and immunotherapy up to two years. Targeted therapies for EGFR, ALK, ROS1, and KRAS mutations may continue indefinitely.

Total treatment costs often exceed one hundred thousand dollars, particularly when immunotherapy or targeted therapy is used. Early‑stage NSCLC has a five‑year survival rate of sixty to seventy percent. Metastatic NSCLC treated with immunotherapy has median survival of approximately two years. SCLC has median survival of twelve to eighteen months for limited‑stage disease and five to seven months for extensive‑stage disease.

Prostate Cancer

Prostate cancer treatment frequently includes surgery, radiation therapy, androgen‑deprivation therapy, and in advanced cases, chemotherapy or targeted therapy. Radiation therapy typically lasts seven to nine weeks. Androgen‑deprivation therapy may continue for two to three years. Chemotherapy regimens such as docetaxel last three to four months.

Total treatment costs range from forty thousand to one hundred thousand dollars. Localized prostate cancer has a five‑year survival rate exceeding ninety‑eight percent. Metastatic castration‑resistant prostate cancer has median survival of approximately two years with modern therapies.

Hematologic Malignancies

Hematologic cancers include leukemias, lymphomas, and myeloma. Treatment duration varies widely. Acute leukemias require multi‑phase chemotherapy lasting six to twelve months. Chronic leukemias may require lifelong targeted therapy. Lymphoma treatment typically lasts three to six months, while multiple myeloma treatment may continue indefinitely with maintenance therapy.

Total treatment costs range from eighty thousand to two hundred fifty thousand dollars. Childhood acute lymphoblastic leukemia has survival rates of eighty to ninety percent. Chronic myeloid leukemia treated with tyrosine kinase inhibitors has ten‑year survival exceeding ninety percent. Multiple myeloma has median survival of five to seven years with modern therapy.

Comparative Summary Table

Cancer Type	Treatment Duration	Cost Range	Survival Outcomes
Breast Cancer	Three months to one year; endocrine therapy up to ten years	Sixty thousand to one hundred fifty thousand dollars	Over ninety percent for early‑stage; three years median for metastatic
Colorectal Cancer	Three to six months; longer for metastatic therapy	Seventy thousand to two hundred thousand dollars	Sixty‑five percent for stage III; twenty to twenty‑four months median for metastatic
Lung Cancer	Three to seven months; immunotherapy up to two years	Over one hundred thousand dollars	Sixty to seventy percent early‑stage; two years median for metastatic NSCLC; five to eighteen months for SCLC
Prostate Cancer	Seven to nine weeks radiation; ADT two to three years	Forty thousand to one hundred thousand dollars	Over ninety‑eight percent localized; two years median for metastatic castration‑resistant
Hematologic Malignancies	Six months to lifelong depending on subtype	Eighty thousand to two hundred fifty thousand dollars	High cure rates for childhood ALL; over ninety percent ten‑year survival for CML; five to seven years median for myeloma

Average Duration, Cost, and Success Rate of Cancer Treatment

Overview

Cancer treatment varies widely depending on cancer type, stage, and modality. Despite this variation, national oncology data allow for meaningful averages across chemotherapy, radiation therapy, targeted therapy, immunotherapy, and surgical intervention. This document presents a structured analysis of the typical duration, cost, and success rate of cancer treatment in the United States, based on 2025–2026 clinical and economic data.

Average Duration of Cancer Treatment

The duration of cancer treatment depends on the treatment modality. Chemotherapy regimens for most solid tumors consist of four to six cycles administered every two or three weeks, resulting in an active treatment period of approximately three to five months. Weekly regimens, such as paclitaxel, typically last twelve weeks. Hematologic malignancies often require multi‑phase protocols extending over many months.

Radiation therapy is generally delivered five days per week for four to seven weeks, depending on dose intensity and cancer type. Targeted therapies and immunotherapies are frequently administered continuously until disease progression or unacceptable toxicity, meaning treatment may extend for years. Surgical treatment is usually a single‑day intervention, but postoperative recovery and adjuvant therapy extend the total treatment period to several months.

Across all cancers, the average active treatment period ranges from three months to one year, with some cancers requiring multi‑year maintenance therapy.

Average Cost of Cancer Treatment

Cancer care is among the most expensive categories of medical treatment in the United States. The average annual cost of a newly approved cancer drug exceeds one hundred thousand dollars. A typical six‑cycle chemotherapy regimen for common solid tumors such as breast or lung cancer costs between twelve thousand and fifteen thousand dollars. Out‑of‑pocket expenses for insured patients average five thousand dollars per year.

For patients receiving multimodal therapy including surgery, chemotherapy, and radiation, total treatment costs often fall between fifty thousand and two hundred thousand dollars. Economic studies show that forty‑two percent of U.S. cancer patients exhaust their life savings within two years of diagnosis. Global oncology drug spending reached one hundred ninety‑six billion dollars in 2022 and continues to rise.

Average Success Rate of Cancer Treatment

Success rates vary dramatically by cancer type, stage, and treatment modality. Across all cancers, the combined five‑year survival rate is approximately sixty‑eight percent. Highly curable cancers such as childhood acute lymphoblastic leukemia, testicular cancer, and early‑stage breast cancer achieve long‑term survival rates between seventy and ninety‑five percent.

Chronic myeloid leukemia treated with tyrosine kinase inhibitors has a ten‑year survival rate exceeding ninety percent. Stage III colorectal cancer shows a five‑ to ten‑percent improvement in disease‑free survival with adjuvant chemotherapy. Metastatic colorectal cancer has response rates of thirty to forty percent and median overall survival of twenty to twenty‑four months. Small‑cell lung cancer demonstrates response rates of twenty to forty percent, with median survival ranging from twelve to eighteen months in limited‑stage disease and five to seven months in extensive‑stage disease.

These figures illustrate the wide range of outcomes across cancer types, from highly curable malignancies to aggressive metastatic diseases with limited long‑term survival.

Summary Table

Category	Typical Range	Description
Treatment Duration	Three months to one year	Chemotherapy typically lasts three to five months; radiation lasts four to seven weeks; targeted therapy and immunotherapy may continue for years.
Cost	Fifty thousand to two hundred thousand dollars	Includes surgery, chemotherapy, radiation, and supportive care; new cancer drugs often exceed one hundred thousand dollars annually.
Success Rate	Ten to ninety‑five percent depending on cancer type	Overall survival is sixty‑eight percent; highly curable cancers exceed seventy percent; aggressive metastatic cancers have lower long‑term survival.

Legal Status of Israeli Settlements and Activities in the West Bank

Overview

The legal status of Israeli settlements in the West Bank has been the subject of extensive international scrutiny. The prevailing international legal consensus, reflected in United Nations resolutions, International Court of Justice opinions, and the interpretations of the International Committee of the Red Cross, is that the settlements violate the Fourth Geneva Convention and constitute unlawful annexation. Israel disputes this interpretation, asserting that the West Bank is disputed territory rather than occupied territory. The following sections present the major legal positions in structured form.

International Legal Framework

The West Bank is treated by the international community as occupied territory. Under the Fourth Geneva Convention, an occupying power is prohibited from transferring parts of its civilian population into the territory it occupies. Article 49(6) is central to this interpretation. The United Nations Security Council has repeatedly reaffirmed that Israeli settlements violate this provision, most notably in Resolutions 446, 478, and 2334. These resolutions describe the settlements as having no legal validity and as constituting a serious obstruction to peace.

The International Court of Justice, in its 2024 advisory opinion, concluded that Israel’s settlement enterprise violates the Palestinian right to self‑determination, constitutes unlawful annexation, and that Israel’s continued presence in the West Bank is itself illegal. The Court rejected Israel’s arguments regarding the applicability of the Geneva Conventions and affirmed that the Convention applies to all cases of occupation, regardless of the prior sovereign status of the territory.

The International Committee of the Red Cross, as the guardian of the Geneva Conventions, also maintains that the settlements violate international humanitarian law. Its interpretation of Article 49(6) is consistent with the UN and ICJ positions.

United Nations Positions

The United Nations General Assembly and Security Council have consistently held that Israeli settlements are illegal. The UN Human Rights Council has described settlement expansion, outposts, infrastructure development, and the displacement of Palestinian communities as grave breaches of international law. Reports from the Office of the High Commissioner for Human Rights state that Israel has taken concerted measures to consolidate annexation through settlement activity, road networks, and administrative integration.

UN Security Council Resolution 2334 (2016) reaffirmed that settlements have “no legal validity” and constitute a “flagrant violation” of international law. The resolution calls for an immediate cessation of settlement activity and emphasizes that the international community will not recognize changes to the 1967 lines other than those agreed by the parties.

Israeli Government Position

Israel disputes the international legal interpretation. It argues that the West Bank is disputed territory because no recognized sovereign existed in 1967. Israel maintains that the Fourth Geneva Convention does not apply de jure to the territories and that Article 49(6) is intended to prohibit forcible transfers, not voluntary settlement. Israel also asserts historical and security claims, as well as the absence of a prior legitimate sovereign, as grounds for its position.

These arguments have been rejected by the International Court of Justice, the United Nations, and the International Committee of the Red Cross. Nonetheless, Israel continues to rely on them as the basis for its domestic legal and political approach to settlement activity.

Comparative Legal Positions

Actor	Legal Status of Settlements	Basis
UN Security Council / General Assembly	Illegal	Fourth Geneva Convention; Resolutions 446, 478, 2334
International Court of Justice (2024)	Illegal; occupation itself unlawful	Advisory opinion on self‑determination, annexation, settlement activity
UN Human Rights Council / OHCHR	Illegal; grave breaches	Fourth Geneva Convention; monitoring reports
International Committee of the Red Cross	Illegal	Interpretation of Geneva Conventions
Government of Israel	Disputed legality	Claims Convention does not apply; no prior sovereign; voluntary migration

Conclusion

The international legal consensus is that Israeli settlements and settlement‑related activities in the West Bank are illegal under international law. Israel disputes this interpretation, but its position is rejected by the International Court of Justice, United Nations bodies, and most states. The settlements are widely viewed as violating the Fourth Geneva Convention, undermining Palestinian self‑determination, and contributing to de facto annexation.

Readers should confirm all information with trusted sources, particularly given the evolving nature of legal and political developments in the region.